CORE-017: CLINICAL PROTOCOL AND DATA MANAGEMENT (CPDM) PROJECT SUMMARY / ABSTRACT The Clinical Protocol and Data Management (CPDM) function of the OSUCCC provides comprehensive resources for the conduct of cancer clinical research with an emphasis on the inclusion of women, minorities, children and other underserved populations. The CPDM is overseen by Dr. William Carson, the Associate Director for Clinical Research (ADCR). The cancer center's Clinical Trials Office (CTO), supports the centralized administration of protocol development, implementation and conduct for all clinically active cancer research groups. No clinical cancer research may be conducted outside the CTO. Thus, the CTO oversees all cancer clinical trials and is the centralized organization for the conduct of such research. This team provides the trial administration, protocol tracking and monitoring, data management, regulatory processing and financial supervision necessary for the successful conduct of clinical trials in a methodologically-sound, expedient, and cost-effective manner. The CTO Medical Director is Steven Devine, MD and the CTO Medical Co-Director is Dr. Bhuvana Ramaswamy, MD. The CTO interim Administrative Director is Nancy Single, PhD. The OSUCCC Data and Safety Monitoring Plan outlines the structure and responsibilities of the Data and Safety Monitoring Committee (DSMC) which oversees and reviews the safe conduct of clinical research at this cancer center. The DSMC is headed by William Blum, MD. The inclusion of women, minorities and children in cancer clinical research is an important goal of this organization and effort in this area are coordinated by the Center for Cancer Health Equity under the leadership of Electra Paskett, PhD, OSUCCC Associate Director for Population Sciences.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-43
Application #
9632733
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Orchard, Tonya S; Andridge, Rebecca R; Yee, Lisa D et al. (2018) Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. J Acad Nutr Diet 118:578-588.e1
Reiff, Sean D; Mantel, Rose; Smith, Lisa L et al. (2018) The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discov 8:1300-1315
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
Qian, Maoxiang; Cao, Xueyuan; Devidas, Meenakshi et al. (2018) TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol 36:591-599
Myers, Regina M; Hill, Brian T; Shaw, Bronwen E et al. (2018) Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer 124:816-825
Nemeth, Julianna M; Thomson, Tiffany L; Lu, Bo et al. (2018) A social-contextual investigation of smoking among rural women: multi-level factors associated with smoking status and considerations for cessation. Rural Remote Health 18:4338
Mace, Thomas A; Shakya, Reena; Pitarresi, Jason R et al. (2018) IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67:320-332
Massengill, James B; Sample, Klarke M; Pilarski, Robert et al. (2018) Analysis of the exome aggregation consortium (ExAC) database suggests that the BAP1-tumor predisposition syndrome is underreported in cancer patients. Genes Chromosomes Cancer 57:478-481
Buteyn, Nathaniel J; Fatehchand, Kavin; Santhanam, Ramasamy et al. (2018) Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. Int Immunol 30:375-383
Hamilton, C A; Miller, A; Casablanca, Y et al. (2018) Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol 148:275-280

Showing the most recent 10 out of 2602 publications